1
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma
Condition(s):CholangiocarcinomaLast Updated:June 5, 2023Not yet recruiting
Trametinib: 269 Clinical Trials, Page 1 of 27
Hide Studies Not Open or Pending
2
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Condition(s):Advanced or Metastatic Solid TumorsLast Updated:August 28, 2023Recruiting
3
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
Condition(s):Low-grade Glioma; Plexiform Neurofibroma; Central Nervous System GliomaLast Updated:October 26, 2022Active, not recruiting
4
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer
Condition(s):Non-small Cell Lung CancerLast Updated:December 3, 2019Terminated
5
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma
Condition(s):Stage IV Melanoma; Stage III MelanomaLast Updated:September 30, 2021Unknown status
6
EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations
Condition(s):Bronchial NeoplasmsLast Updated:November 3, 2022Recruiting
7
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple MyelomaLast Updated:August 30, 2023Active, not recruiting
8
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple MyelomaLast Updated:August 29, 2023Active, not recruiting
9
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
Condition(s):Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple MyelomaLast Updated:June 27, 2023Active, not recruiting
10
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
Condition(s):CancerLast Updated:September 14, 2018Withdrawn